Insulin-Like-Growth Factor-Binding-Protein 7: An Antagonist to Breast Cancer

Benatar, Tania; Amemiya, Yutaka; Yang, Wenyi; Seth, Arun

doi:10.5772/21700

Cited by 1 publication

(1 citation statement)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IGFBP7 had very strong physical interactions with CCL21 and shared protein domains with SPARCL1, indicating that CCL21, IGFBP7 and SPARCL1 might be functionally related. IGFBP7 has been identified as one of these factors responsible for the establishment and/or maintenance of oncogene-induced senescence, and has been shown to be a TSG in a variety of solid cancers (60). Aberrant expression of IGFBP7 in adult leukemia is correlated with chemotherapy resistance and shorter survival.…”

Section: Function Prediction and Analysis Based On Interaction Networkmentioning

confidence: 99%

Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer

Yin

Liu

et al. 2013

International Journal of Oncology

View full text Add to dashboard Cite

Chemokine (C-C motif) ligand 21 (CCL21) and SPARC-like protein 1 (SPARCL1/MAST9/hevin/SC-1) are associated with various biological behavior in the development of cancers. Although the expression of CCL21 and SPARCL1 is downregulated in many solid tumors, their roles in ovarian cancer and their associations with drug resistance have rarely been studied. We performed a comprehensive bioinformatic analysis consisting of motif analysis, literature co-occurrence, gene/protein-gene/protein interaction network, protein-small molecule interaction network, and microRNAs enrichments which revealed that CCL21 and SPARCL1 directly or indirectly interact with a number of genes, proteins, small molecules and pathways associated with drug resistance in ovarian and other cancers. These results suggested that CCL21 and SPARCL1 may contribute to drug resistance in ovarian cancer. This study provided important information for further investigation of drug resistance-related functions of CCL21 and SPARCL1 in ovarian cancer.

show abstract

Section: Function Prediction and Analysis Based On Interaction Networkmentioning

confidence: 99%